LEQEMBI — Expense reflected within statements of income
Biogen LEQEMBI — Expense reflected within statements of income decreased by 3.8% to $84.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.6%, from $88.80M to $84.70M. Over 3 years (FY 2022 to FY 2025), LEQEMBI — Expense reflected within statements of income shows an upward trend with a 26.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase directly reduces reported operating margins, reflecting the company's share of the financial burden for the product's development or commercialization.
Detailed definition
This metric represents the portion of collaborative development or operating expenses that is recognized directly on the...
Peer comparison
Similar to equity method accounting or shared expense recognition in collaborative pharmaceutical arrangements.
biib_segment_leqembi_expense_reflected_within_statements_of_incomeHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $43.40M | $43.40M | $43.40M | $43.40M | $46.50M | $46.50M | $46.50M | $46.50M | $86.90M | $68.90M | $82.30M | $85.40M | $88.80M | $85.70M | $88.30M | $88.00M | $84.70M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +7.1% | +0.0% | +0.0% | +0.0% | +86.9% | -20.7% | +19.4% | +3.8% | +4.0% | -3.5% | +3.0% | -0.3% | -3.8% |
| YoY Change | — | — | — | — | +7.1% | +7.1% | +7.1% | +7.1% | +86.9% | +48.2% | +77.0% | +83.7% | +2.2% | +24.4% | +7.3% | +3.0% | -4.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's leqembi — expense reflected within statements of income?
- Biogen (BIIB) reported leqembi — expense reflected within statements of income of $84.70M in Q1 2026.
- How has Biogen's leqembi — expense reflected within statements of income changed year-over-year?
- Biogen's leqembi — expense reflected within statements of income decreased by 4.6% year-over-year, from $88.80M to $84.70M.
- What is the long-term trend for Biogen's leqembi — expense reflected within statements of income?
- Over 3 years (2022 to 2025), Biogen's leqembi — expense reflected within statements of income has grown at a 26.4% compound annual growth rate (CAGR), from $173.60M to $350.80M.
- What does leqembi — expense reflected within statements of income mean?
- The portion of partnership-related expenses that directly impacts the company's reported net income.